Department of Ophthalmology, University of Rome "Sapienza," Polo Pontino, "A. Fiorini" Hospital, Terracina.
Can J Ophthalmol. 2013 Oct;48(5):394-9. doi: 10.1016/j.jcjo.2013.04.006.
To evaluate which of 2 measuring units (bivariate contour ellipse area [BCEA] vs Fujii) yields more accurate measurements of fixation stability, obtained using the MP-1 device, in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal injections of ranibizumab, during a 12-month follow-up period.
Small retrospective, noncomparative, interventional case series.
A total of 25 eyes in 25 patients (13 males, 12 females; mean age 71.72 ± 7.98 years).
All participants were older than 50 years, diagnosed with active subfoveal choroidal neovascularization, had best corrected visual acuity (BCVA) values above 20/100, and all lesion types were included. All patients underwent a loading phase with 3 consecutive intravitreal injections of 0.05 mg ranibizumab at monthly intervals. Patients were retreated after the third injection if they exhibited a 100-μm increase in macular thickness or evidence of intraretinal and/or subretinal fluid and new subretinal hemorrhage, observed with spectral-domain optical coherence tomography and fluorescein angiography. The data collected included BCVA and mean macular sensitivities, BCEA, and fixation patterns, performed at baseline and at months 4 and 12, using the MP-1 device.
The mean total injection number was 5.92 ± 1.18 (minimum 3, maximum 8). Mean BCVA at baseline was 0.55 ± 0.28 logMAR and increased significantly to 0.50 ± 0.33 logMAR. Mean macular sensitivity at baseline was 7.06 ± 4.59 dB and increased significantly to 8.40 ± 4.82. Mean BCEA was 2.19 ± 1.38 deg(2) and decreased significantly to 1.68 ± 1.43 deg(2). Fixation stability patterns, according to the protocol set out by Fujii, did not change significantly during follow-up.
Compared with Fujii fixation stability patterns, BCEA correlated better with variations in macular sensitivity and BCVA. BCEA can be added to the traditional parameters used to evaluate the efficacy of intravitreal injections in patients with nAMD.
评估在接受玻璃体腔内雷珠单抗注射治疗的新生血管性年龄相关性黄斑变性（nAMD）患者中，使用 MP-1 设备在 12 个月的随访期间，两种测量单位（双变量轮廓椭圆面积 [BCEA] 与 Fujii）中哪一种能更准确地测量固视稳定性。
小回顾性、非对照、干预性病例系列。
共纳入 25 例 25 只眼（13 名男性，12 名女性；平均年龄 71.72±7.98 岁）。
所有参与者年龄均大于 50 岁，诊断为活动性黄斑下脉络膜新生血管，最佳矫正视力（BCVA）值高于 20/100，所有病变类型均包括在内。所有患者均接受连续 3 次玻璃体腔内注射 0.05mg 雷珠单抗的负荷期治疗，每月 1 次。如果患者的黄斑厚度增加 100μm，或眼底照相和荧光素血管造影显示存在视网膜内和/或视网膜下液及新的视网膜下出血，将在第三次注射后进行再次治疗。使用 MP-1 设备在基线和第 4 个月及第 12 个月时收集 BCVA 和平均黄斑敏感性、BCEA 和固视模式的数据。
平均总注射次数为 5.92±1.18（最少 3 次，最多 8 次）。基线时的平均 BCVA 为 0.55±0.28 logMAR，显著增加至 0.50±0.33 logMAR。基线时平均黄斑敏感性为 7.06±4.59dB，显著增加至 8.40±4.82dB。平均 BCEA 为 2.19±1.38deg²，并显著减少至 1.68±1.43deg²。根据 Fujii 制定的方案，固视稳定性模式在随访期间无显著变化。
与 Fujii 固视稳定性模式相比，BCEA 与黄斑敏感性和 BCVA 的变化相关性更好。BCEA 可作为评估 nAMD 患者玻璃体腔内注射疗效的传统参数之外的附加参数。
